Gian Marco Tosi1, Jurgen Sota2, Antonio Vitale2, Donato Rigante3, Giacomo Emmi4, Giuseppe Lopalco5, Silvana Guerriero6, Ida Orlando2, Florenzo Iannone5, Bruno Frediani2, Rossella Angotti7, Mario Messina7, Mauro Galeazzi2, Lorenzo Vannozzi8, Luca Cantarini9, Claudia Fabiani1. 1. Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Italy. 2. Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy. 3. Institute of Paediatrics, Università Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S., Rome, Italy. 4. Department of Experimental and Clinical Medicine, University of Florence, Italy. 5. Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari, Italy. 6. Department of Ophthalmology and Otolaryngology, University of Bari, Italy. 7. Division of Paediatric Surgery, Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy. 8. Department of Surgery and Translational Medicine, Eye Clinic, University of Florence, Italy. 9. Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy. cantariniluca@hotmail.com.
Abstract
OBJECTIVES: The aim of the study was to evaluate the efficacy of golimumab (GOL) and certolizumab pegol (CZP) as additional treatment options for the treatment of uveitis. METHODS: Patients with longstanding uveitis receiving either GOL or CZP were retrospectively evaluated in terms of frequency of ocular flares, drug survival, changes in best corrected visual acuity (BCVA) and steroid-sparing effect. RESULTS: Twenty-one patients (30 eyes), 17 of whom being female, were enrolled in the study; 16 out of 21 patients had been previously treated with other tumour necrosis factor (TNF)-α blockers. A significant reduction in ocular flares (from 128.6 bouts for 100 patients-year to 42.9 events for 100 patients-year) was observed between the 12 months prior to the start of GOL or CZP and the 12 months thereafter (p=0.01). The 36-month drug survival was 54.5% for CZP and 50.0% for GOL with no statistically significant differences between the two biologic agents. No differences were detected concerning BCVA values and the mean corticosteroid intake between baseline and the last follow-up. The safety profile was excellent. CONCLUSIONS: GOL and CZP represent effective and safe treatment choices for patients with uveitis also when unsuccessfully treated with other anti-TNF-α drugs, permitting a significant reduction in the frequency of ocular flares and preserving visual function with a good long-term retention rate.
OBJECTIVES: The aim of the study was to evaluate the efficacy of golimumab (GOL) and certolizumab pegol (CZP) as additional treatment options for the treatment of uveitis. METHODS:Patients with longstanding uveitis receiving either GOL or CZP were retrospectively evaluated in terms of frequency of ocular flares, drug survival, changes in best corrected visual acuity (BCVA) and steroid-sparing effect. RESULTS: Twenty-one patients (30 eyes), 17 of whom being female, were enrolled in the study; 16 out of 21 patients had been previously treated with other tumour necrosis factor (TNF)-α blockers. A significant reduction in ocular flares (from 128.6 bouts for 100 patients-year to 42.9 events for 100 patients-year) was observed between the 12 months prior to the start of GOL or CZP and the 12 months thereafter (p=0.01). The 36-month drug survival was 54.5% for CZP and 50.0% for GOL with no statistically significant differences between the two biologic agents. No differences were detected concerning BCVA values and the mean corticosteroid intake between baseline and the last follow-up. The safety profile was excellent. CONCLUSIONS: GOL and CZP represent effective and safe treatment choices for patients with uveitis also when unsuccessfully treated with other anti-TNF-α drugs, permitting a significant reduction in the frequency of ocular flares and preserving visual function with a good long-term retention rate.
Authors: Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Arianna Sgheri; Giuseppe Lopalco; Jurgen Sota; Silvana Guerriero; Florenzo Iannone; Bruno Frediani; Lorenzo Vannozzi; Maria Teresa Bianco; Valtere Giovannini; Gian Marco Tosi; Luca Cantarini Journal: Front Pharmacol Date: 2019-12-09 Impact factor: 5.810
Authors: Irene E van der Horst-Bruinsma; Philip C Robinson; Ennio G Favalli; Frank D Verbraak; Mindy Kim; Thomas Kumke; Lars Bauer; Bengt Hoepken; Atul Deodhar Journal: Rheumatol Ther Date: 2022-09-30
Authors: Irene van der Horst-Bruinsma; Rianne van Bentum; Frank D Verbraak; Thomas Rath; James T Rosenbaum; Maria Misterska-Skora; Bengt Hoepken; Oscar Irvin-Sellers; Brenda VanLunen; Lars Bauer; Martin Rudwaleit Journal: RMD Open Date: 2020-04